Allscripts Healthcare Solutions (MDRX) Receiving Positive Press Coverage, Study Finds

Press coverage about Allscripts Healthcare Solutions (NASDAQ:MDRX) has been trending positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allscripts Healthcare Solutions earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave news coverage about the software maker an impact score of 45.9119074114253 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Allscripts Healthcare Solutions (NASDAQ MDRX) opened at $14.65 on Monday. The company has a market capitalization of $2,646.98, a PE ratio of 34.07, a price-to-earnings-growth ratio of 2.61 and a beta of 1.34. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 1.20. Allscripts Healthcare Solutions has a 12 month low of $10.19 and a 12 month high of $15.20.

MDRX has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Cowen raised shares of Allscripts Healthcare Solutions from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $13.00 to $16.00 in a research report on Monday, September 11th. Royal Bank of Canada began coverage on shares of Allscripts Healthcare Solutions in a research report on Tuesday, September 19th. They set an “outperform” rating and a $17.00 price objective for the company. Jefferies Group set a $17.00 price objective on shares of Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, Maxim Group reissued a “buy” rating and set a $16.00 target price on shares of Allscripts Healthcare Solutions in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.06.

In related news, SVP James Hewitt sold 36,796 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $14.11, for a total value of $519,191.56. Following the completion of the sale, the senior vice president now owns 181,766 shares in the company, valued at approximately $2,564,718.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.75% of the company’s stock.

WARNING: “Allscripts Healthcare Solutions (MDRX) Receiving Positive Press Coverage, Study Finds” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Insider Buying and Selling by Quarter for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with's FREE daily email newsletter.

Leave a Reply